[ Price : $8.95]
FDA approves Bristol-Myers Squibbs Opdivo (nivolumab) for treating patients with recurrent or metastatic squamous cell carcinoma o...[ Price : $8.95]
Former FDAer Wayne Pines outlines three impacts of the election results on FDA in the future.[ Price : $8.95]
Drug and device industries urge FDA to revise its off-label dissemination policies to allow needed dialogs with payers and the med...[ Price : $8.95]
Consumers for Dental Choice asks FDA to take three steps to warn dentists, parents, and dental consumers against amalgam use in ch...[ Price : $8.95]
Political analysts see the possibility for compromise 21st Century Cures legislation to be approved by the lame duck Congress that...[ Price : $8.95]
Sen. Chuck Grassley asks the HHS inspector general for records relating its 2009 determination that the EpiPen had been misclassif...[ Price : $8.95]
CDER issues a MAPP on the review of INDs and NDAs for botanical drug products.